PMID- 29581353
OWN - NLM
STAT- MEDLINE
DCOM- 20190920
LR  - 20190920
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 103
IP  - 1
DP  - 2019 Jan
TI  - Optical coherence tomography angiography in comparison with other multimodal 
      imaging techniques in punctate inner choroidopathy.
PG  - 60-66
LID - 10.1136/bjophthalmol-2017-311764 [doi]
AB  - AIMS: To characterise punctate lesions and choroidal neovascularisation (CNV) in 
      eyes with punctate inner choroidopathy (PIC) using current standard multimodal 
      imaging techniques and optical coherence tomography angiography (OCTA). METHODS: 
      In our prospective, single-centre study, 20 individuals with PIC underwent 
      imaging with spectral-domain optical coherence tomography (SD-OCT), fluorescein 
      angiography (FA), indocyanine green angiography, fundus autofluorescence, fundus 
      colour photography and OCTA. RESULTS: Thirty-two eyes of 20 patients were 
      affected. Eight (20%) eyes revealed typical punctate lesions, while 24 (60%) eyes 
      had confirmed CNV on SD-OCT and FA in addition to punctate lesions. Of these 24 
      eyes with CNV, a reoccurrence of active CNV was detected in 5 (21%) eyes, a 
      residual fluid in 3 (13%) eyes, while 16 (67%) eyes were defined as being stable. 
      On OCTA, CNV was classified as having 'lacy wheel', 'pruned large-trunk' and 
      'dead tree aspect' vessel shapes with or without areas of non-perfusion. The 
      disease activity was dependent on several predictors in the regression analysis 
      such as intraretinal fluid (p=0.0014), CNV type (p=0.0199), leakage (p<0.0001) 
      and hypoperfusion/non-perfusion (p<0.0001) on OCTA. CONCLUSION: OCTA offers 
      additional valuable insight into the current standard multimodal imaging 
      techniques used for characterisation of PIC. This imaging technique can be a 
      useful tool for analysis of disease activity.
CI  - (c) Article author(s) (or their employer(s) unless otherwise stated in the text of 
      the article) 2019. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Pohlmann, Dominika
AU  - Pohlmann D
AD  - Department of Ophthalmology, Charite - Universitatsmedizin Berlin, corporate 
      member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health, Berlin, Germany.
FAU - Pleyer, Uwe
AU  - Pleyer U
AD  - Department of Ophthalmology, Charite - Universitatsmedizin Berlin, corporate 
      member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health, Berlin, Germany.
FAU - Joussen, Antonia M
AU  - Joussen AM
AD  - Department of Ophthalmology, Charite - Universitatsmedizin Berlin, corporate 
      member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health, Berlin, Germany.
FAU - Winterhalter, Sibylle
AU  - Winterhalter S
AD  - Department of Ophthalmology, Charite - Universitatsmedizin Berlin, corporate 
      member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health, Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20180326
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
SB  - IM
MH  - Adult
MH  - Choroid/blood supply/diagnostic imaging
MH  - Female
MH  - Fluorescein Angiography/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging/methods
MH  - Optical Imaging/methods
MH  - Tomography, Optical Coherence/*methods
MH  - Uveitis, Posterior/*diagnostic imaging
OTO - NOTNLM
OT  - imaging
OT  - immunology
OT  - macula
OT  - retina
COIS- Competing interests: UP has served as principal investigator or consultant for: 
      Abbvie, Alcon, Allergan, Novartis, Santen and Thea. AMJ has served as principal 
      investigator or consultant for: Allergan, Novartis, Bayer, OD-OS and Heidelberg 
      engineering. SW has served as consultant for: Allergan, Novartis, Bayer, MSD and 
      Heidelberg engineering. None of the authors has a direct proprietary interest in 
      any of the products used in this study.
EDAT- 2018/03/28 06:00
MHDA- 2019/09/21 06:00
CRDT- 2018/03/28 06:00
PHST- 2017/12/19 00:00 [received]
PHST- 2018/02/20 00:00 [revised]
PHST- 2018/03/05 00:00 [accepted]
PHST- 2018/03/28 06:00 [pubmed]
PHST- 2019/09/21 06:00 [medline]
PHST- 2018/03/28 06:00 [entrez]
AID - bjophthalmol-2017-311764 [pii]
AID - 10.1136/bjophthalmol-2017-311764 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2019 Jan;103(1):60-66. doi: 10.1136/bjophthalmol-2017-311764. 
      Epub 2018 Mar 26.